Name: MPTP Hydrochloride
Brand: Selleck Chemicals
SKU: S4732
Rating: 5 (29 reviews)

Jump to

Quality Control

Batch: Purity: 99.94%

99.94

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Dopamine Receptor Inhibitors	Trifluoperazine Trifluoperazine 2HCl Penfluridol Sulpiride Levosulpiride SCH-23390 hydrochloride Domperidone Rotundine Azaperone SKF38393 HCl

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
insect cells	Function assay	120 mins	Inhibition of human recombinant MAOA expressed in insect cells assessed as oxidation of kynuramine substrate at 50 uM measured after additional enzyme added after 120 mins incubation	22078410
insect cells	Function assay	90 mins	Inhibition of human recombinant MAOA expressed in insect cells assessed as oxidation of kynuramine substrate at 50 uM measured after additional substrate added after 90 mins incubation	22078410
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	209.72	Formula	C₁₂H₁₅N·HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	23007-85-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CN1CCC(=CC1)C2=CC=CC=C2.Cl

Solubility

In vitro
Batch:

Water : 41 mg/mL

Ethanol : 41 mg/mL

DMSO : 26 mg/mL (123.97 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.100mg/ml (10.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 42 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	The morphology of N2AB-1 and glioma cells was unaltered when these cells were exposed to all doses of MPTP Hydrochloride. And, C6 glioma cell proliferation was also unaffected by this compound treatment. MPTP Promotes Apoptosis and Tau Phosphorylation in Human Neuroblastoma M17 Cells. This compound significantly promotes Tau phosphorylation at Ser262 in human neuroblastoma M17 cells. It caused a dose-dependent increase in the intracellular α-synuclein level in our M17 human neuroblastoma cells. This chemical appears to promote Tau phosphorylation in the brain by activating both PKA and GSK3β.
In vivo	The number of tyrosine hydroxylase-positive neurons was decreased in the substantia nigra pars compacta of MPTP-treated mice. This compound decreased thioredoxin reductase 1 expression and thioredoxin reductase activity in the mouse midbrain, reduced the number of thioredoxin reductase 1-positive cells in the substantia nigra pars compacta of mice. Administration of this toxin can cause neurochemical, behavioral and histopathological alterations in human and nonhuman primates that are similar to those observed in Parkinsonian patients. Compared with primates, rodents are insensitive to MPTP. This chemical can be administered by various routes, such as gavage and stereotactic injection, but the most common and reproducible route is systemic administration, including subcutaneous, intravenous, intraperitoneal and intramuscular injection. It is a lipophilic protoxin that can rapidly cross the blood-brain barrier following systemic injection. Once it enters the brain, MPTP is converted to 1-methyl-4-phenylpyridine by monoamine oxidase B. It has been shown to be toxic to dopaminergic neurons of the nigrostriatal system in humans, monkeys, and mice and to produce long-lasting depletion of DA and its metabolites in the striatum.
References	[1] https://pubmed.ncbi.nlm.nih.gov/25206649/ [2] https://pubmed.ncbi.nlm.nih.gov/12200191/ [3] https://pubmed.ncbi.nlm.nih.gov/3264740/ [4] https://pubmed.ncbi.nlm.nih.gov/21127069/

Applications

Methods	Biomarkers	PMID
Western blot	TH / Actin pCaMKIIβ / pCaMKIIα / CaMKIIβ / CaMKIIα / β-Actin TH / p-α-Syn / α-Syn / β-actin / CDK5 / LC3-I / LC3-II / p62 / NLRP3 / ASC / Casp1 p20 / Procasp1 p-ERK1/2 / ERK1/2 / GAPDH GDH2 / GDH1 / GFAP / GAPDH	23391753
IHC	tyrosine hydroxylase (TH) tyrosine hydroxylase (TH) SNpc tyrosine hydroxylase (TH) Substantia nigra	31427934
Immunofluorescence	tyrosine hydroxylase (TH) / miR-188-3p α-Syn tyrosine hydroxylase (TH) / Tunel tyrosine hydroxylase (TH) / Tunel tyrosine hydroxylase (TH) GFAP	33717653